10.86SEK-1.63%Mkt Cap: 297.29M $P/E: —Today
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap297.29M $
Enterprise Value195.92M $
Revenue (TTM)337.37K $
Gross Profit365.10K $
Net Income (TTM)-45.67M $
Revenue/Share0.0013 USD
Last Price10.86 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.82
PEG—
EV/EBITDA—
EV/Revenue580.73
P/S892.39
P/B3.18
EPS (TTM)-1.90
EPS (Forward)-1.92
52W Range
8.62023% of range18.24
52W High18.24 SEK
52W Low8.620 SEK
Profitability
Gross Margin100.00%
Oper. Margin-20515.78%
EBITDA Margin0.00%
Profit Margin-12509.14%
ROE-43.59%
ROA-39.18%
Growth
Revenue Growth-32.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.94M $
CapEx (TTM)—
FCF Margin-6860.66%
FCF Yield-7.79%
Net Debt-101.37M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio12.69
Quick Ratio12.57
Book Value/Sh3.520 SEK
Cash/Share3.764 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)29.25 SEK
Upside (mean)+169.3%
Target Range15.00 SEK – 38.00 SEK
SEK15.00+169.3% to meanSEK38.00
# Analysts4
Ownership
Shares Out.281.53M
Float198.62M
Insiders12.75%
Institutions59.51%
Technical
SMA 5011.71 (-7.3%)
SMA 20010.88 (-0.1%)
Beta0.12
S&P 52W Chg18.16%
Avg Vol (30d)484.04K
Avg Vol (10d)557.52K
Technical Indicators
RSI (14)44.8
MACD-0.1247
MACD Signal-0.1288
MACD Hist.+0.0041
BB Upper11.67 SEK
BB Middle11.20 SEK
BB Lower10.73 SEK
BB Width8.38%
ATR (14)0.5228 SEK
Vol Ratio (20d)0.68x